Long-term effects of pegvisomant in patients with acromegaly

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 6, 2008, Pages 324-332

  Hodish, Israel ^a   Barkan, Ariel ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acromegaly; Pegvisomant

Indexed keywords

AMINOTRANSFERASE; GLUCOCORTICOID; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BONE METABOLISM; CARDIOVASCULAR RISK; CHOLESTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GLUCOSE METABOLISM; HEADACHE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOPHYSIS TUMOR; INJECTION SITE CONTUSION; LIPOHYPERTROPHY; LIVER CELL DAMAGE; LIVER DYSFUNCTION; MONOTHERAPY; MORTALITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SURGICAL TECHNIQUE; TACHYPHYLAXIS; TUMOR GROWTH; TUMOR VOLUME;

ACROMEGALY; BONE AND BONES; DRUG THERAPY, COMBINATION; GLUCOSE; HEART; HUMAN GROWTH HORMONE; HUMANS; LIPIDS; LIVER; PITUITARY NEOPLASMS; RECEPTORS, SOMATOTROPIN;

EID: 44349091055     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0831     Document Type: Review

References (61)

1. Rajasoorya C et al. (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41: 95-102
2. Freda PU et al. (1998) Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89: 353-358
3. Swearingen B et al. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83: 3419-3426
4. Giustina A et al. (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526-529
5. Kopchick JJ et al. (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23: 623-646
6. Stewart PM (2000) Current therapy for acromegaly. Trends Endocrinol Metab 11: 128-132
7. Kopchick JJ (2003) Discovery and mechanism of action of pegvisomant. Eur J Endocrinol 148 (Suppl 2): S21-S25
8. Cunningham BC and Wells JA (1991) Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci USA 88: 3407-3411
9. Wells JA et al. (1993) The molecular basis for growth hormone-receptor interactions. Recent Prog Horm Res 48: 253-275
10. Goffin V et al. (1999) The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 140: 3853-3856
11. Harding PA et al. (1996) Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J Biol Chem 271: 6708-6712
12. Ross RJ et al. (2001) Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86: 1716-1723
13. Maamra M et al. (1999) Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling. J Biol Chem 274: 14791-14798
14. Clark R et al. (1996) Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271: 21969-21977
15. Drake WM et al. (2001) Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol Metab 12: 408-413
16. Trainer PJ et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177
17. van der Lely AJ et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358: 1754-1759
18. Colao A et al. (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154: 467-477
19. Schreiber I et al. (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156: 75-82
20. Parkinson C et al. (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92: 190-195
21. Veldhuis JD et al. (2001) Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-PEG), augments the amplitude of GH secretory bursts and elevates basal/ nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab 86: 3304-3310
22. Jørgensen JO et al. (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90: 5627-5631
23. Feenstra J et al. (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365: 1644-1646
24. Neggers SJ et al. (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92: 4598-4601
25. th Annual Meeting, June 2-5; Toronto
26. Thirone AC et al. (1997) Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues. Mol Cell Endocrinol 130: 33-42
27. Rizza RA et al. (1982) Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31: 663-669
28. Rosenfeld RG et al. (1982) Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J Clin Endocrinol Metab 54: 1033-1038
29. Ezzat S et al. (1994) Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 73: 233-240
30. Jaffrain-Rea ML et al. (2001) Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 54: 189-195
31. Colao A et al. (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85: 193-199
32. Lindberg-Larsen R et al. (2007) The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92: 1724-1728
33. Muller AF et al. (2001) Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency. J Clin Endocrinol Metab 86: 5165-5171
34. Barkan AL et al. (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90: 5684-5691
35. Parkinson C et al. (2002) A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87: 1797-1804
36. Nikkila EA and Pelkonen R (1975) Serum lipids in acromegaly. Metabolism 24: 829-838
37. Takeda R et al. (1982) The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients. Acta Endocrinol (Copenh) 100: 358-362
38. Wildbrett J et al. (1997) Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 105: 331-335
39. Oscarsson J et al. (1994) Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clin Endocrinol (Oxf) 41: 603-608
40. Sesmilo G et al. (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87: 1692-1699
41. James RA et al. (1991) Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabet Med 8: 517-523
42. Paisley AN et al. (2006) Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. J Clin Endocrinol Metab 91: 4635-4640
43. Clayton RN (2003) Cardiovascular function in acromegaly. Endocr Rev 24: 272-277
44. Vitale G et al. (2001) Cardiovascular complications in acromegaly: methods of assessment. Pituitary 4: 251-257
45. Wright AD et al. (1970) Mortality in acromegaly. QJ Med 39: 1-16
46. Abosch A et al. (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83: 3411-3418
47. Nabarro JD (1987) Acromegaly. Clin Endocrinol (Oxf) 26: 481-512
48. Bengtsson BA et al. (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223: 327-335
49. Pivonello R et al. (2007) Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 92: 476-482
50. Ezzat S et al. (1993) Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 76: 1452-1457
51. Parkinson C et al. (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88: 5650-5655
52. Trainer PJ et al. (2001) Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 86: 2989-2992
53. Rodriguez-Arnao J et al. (1996) Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 45: 33-37
54. Yin D et al. (2007) Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 13: 1000-1009
55. van der Lely AJ et al. (2001) Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86: 478-481
56. Frohman LA and Bonert V (2007) Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 10: 283-289
57. Biering H et al. (2006) Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154: 213-220
58. Maffei P et al. (2006) Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 145: 310-312
59. Qureshi A et al. (2006) IVF/ICSI in a woman with active acromegaly: successful outcome following treatment with pegvisomant. J Assist Reprod Genet 23: 439-442
60. Brian SR et al. (2007) Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92: 3374-3377
61. Jehle S et al. (2005) Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 90: 1588-1593